FDA Approved: SOVUNA — Supplemental Application (ANI Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SOVUNA (hydroxychloroquine sulfate) submitted by ANI Pharmaceuticals, under NDA 214581.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• SOVUNA (Hydroxychloroquine sulfate)

Snippet

SUPPL AP for SOVUNA (HYDROXYCHLOROQUINE SULFATE)